Elsevier and European Alliance of Associations for Rheumatology announce new partnership

The European Alliance of Associations for Rheumatology (EULAR) announces a new partnership with Elsevier, a global leader in information and analytics, to publish its flagship scientific journal, Annals of the Rheumatic Diseases (ARD). The journal will be hosted on Elsevier’s leading online platform, ScienceDirect, beginning January 2025

“We are delighted that our flagship journal will continue its successful journey with the world's largest publisher and feel that this partnership will equip us ideally for the challenges of the future,” said Professor Daniel Aletaha, EULAR President.

Professor Josef Smolen, ARD Editor-in-Chief, adds: “Authors, researchers and readers can expect a seamless transition while maintaining the journal's high standards and commitment to excellence.”

Originally published in 1939, ARD has always strived for excellence in research advances and novel clinical insights. Thus, it continues to be the leading rheumatology journal publishing high-quality scientific papers, original research, reviews, recommendations, viewpoints, and more. Basic, clinical, and translational scientific research across the inflammatory and non-inflammatory musculoskeletal conditions is part and parcel of this spectrum.

The journal’s authors, reviewers and editors volunteer their time and expertise to contribute and disseminate this important scientific information to the international research community with a hybrid subscription-based model. Its current (2023) Impact Factor of 20.3 places it second overall in the Rheumatology subject category and first among the journals publishing original research advances. The 2023 CiteScore of 35 places it in the #1/73 (99^th percentile) position in the category Medicine/Rheumatology.

“We are very honoured to be chosen as the publishing partner for EULAR. Elsevier is committed to providing EULAR with a trusted platform, addressing customer needs, and providing insight through data analytics. Our collaboration will further support both organisations’ efforts to improve health outcomes”, stated Carl Schwarz, Senior Vice President, Health and Medical Sciences at Elsevier. “ARD is a hugely respected journal in the rheumatology field and will be a great fit with our rheumatology portfolio. We are very proud that EULAR has chosen to partner with us and look forward to helping them and ARD transition to Elsevier,” added Tanya Wheatley, Elsevier’s Executive Publisher for Rheumatology.

About the European Alliance of Associations for Rheumatology (EULAR)

EULAR is the European umbrella organisation representing scientific societies, health professional associations and organisations for people with rheumatic and musculoskeletal diseases (RMDs). EULAR aims to reduce the impact of RMDs on individuals and society, as well as improve RMD treatments, prevention, and rehabilitation. To this end, EULAR fosters excellence in rheumatology education and research, promotes the translation of research advances into daily care, and advocates for the recognition of the needs of those living with RMDs by EU institutions.

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야의 글로벌 선도 기업이다. 100년 넘게 과학과 헬스케어의 발전을 지원하며 인류 진보에 기여해 왔다. 전 세계 170개국에서 학계 및 기업 연구 커뮤니티와 의사, 간호사, 미래 의료 전문가, 교육자들이 수행하는 중요한 업무를 지원한다. 세계 최고 수준의 근거 기반 과학·의학 콘텐츠와 정밀 AI, 전문가 평가를 토대로 구축한 연구 및 임상 등급 솔루션을 제공하여 의미 있는 변화를 만들어가는 사람들에게 더 나은 성과를 거둘 수 있도록 돕는다. 또한 포용성과 지속가능성 증진에 앞장서며 엘스비어가 지원하는 커뮤니티와 협력한다. 엘스비어 재단(The Elsevier Foundationopens in new tab/window)은 전 세계의 연구 및 보건 파트너십을 지원한다.

엘스비어는 전문가 및 기업 고객에게 정보 기반 분석과 의사결정 도구를 제공하는 글로벌 기업 RELXopens in new tab/window의 일원이다. 자세한 내용은 www.elsevier.com에서 확인할 수 있으며, 소셜미디어 @elsevierconnect를 통해 최신 소식을 받아볼 수 있다.